DIRS.INFO The most relevant business & tech news

When you’re an NFL head coach, you’re in charge of a lot of things. Brian Callahan, the first-year head coach of the Tennessee Titans, is now overseeing aspects he didn’t have to think about before as an assistant. He was head coach of the Oakland Raiders from 2002 to 2003 and the University of Nebraska from 2004 to 2007. Tennessee Titans head coach Brian Callahan. “Sometimes I’ll call them ‘Coach Bill’; sometimes I’ll call Brian ‘Coach Cally.’ I mean, whatever comes out.”Running backs coach Randy Jordan remembers getting confused early on.

Persons: you’re, Brian Callahan, Bill Callahan, “, Bill, “ We’re, Brian, ” Brian, ” Bill, Cleveland, Justin Ford, ’, Lloyd Cushenberry, Bill ’, Brian ‘, Cally, Randy Jordan, Nick Holz, it’s, ” Holz, that’s, ”, It’s Organizations: NFL, Tennessee Titans, NBC News, Oakland Raiders, University of Nebraska, Cleveland Browns, Getty, The Titans, Cincinnati Bengals, Browns, National Football League, Titans

☆ GLP-1 pills are coming, and they could revolutionize weight-loss treatment
▼ + stars: | 2024-09-17 | by ( Meg Tirrell | ) edition.cnn.com time to read: +7 min

CNN —Jared Holz thought about taking one of the new GLP-1 drugs for weight loss for months before he actually filled the prescription. At least a dozen similar experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, with the most advanced now in the third and final stage of testing. Dushay cited hopes that pill versions of GLP-1 drugs could ease shortages, come at lower cost and enhance convenience. The oral GLP-1 raceRight on the heels of oral semaglutide is a group of drugs led by Eli Lilly’s orforglipron, an oral medication that also targets GLP-1, which is a hormone implicated in insulin regulation, appetite and digestion. Drugmakers including Pfizer and Roche, as well as smaller companies like Structure Therapeutics, Terns Pharmaceuticals and Viking Therapeutics, also have oral weight-loss drugs in earlier stages of development, BMO research shows.

Persons: Jared Holz, ” Holz, ”, Jody Dushay, Dushay, ” Dushay, it’s, Rybelsus, Jorge Moreno, “, ” Moreno, Eli Lilly’s orforglipron, Lilly, Evan Seigerman, amycretin, who’ve, Dr, Sanjay Gupta, Holz, he’s, he’d Organizations: CNN, Harvard Medical School, Beth Israel Deaconess Medical, Novo Nordisk, US Food and Drug Administration, Yale School of Medicine, BMO Capital Markets, Pfizer, Roche, Therapeutics, Terns Pharmaceuticals, Viking Therapeutics, BMO, Nordisk, European Association for, Diabetes, Inversago Pharma, CNN Health Locations: Danish, Novo

☆ Novo Nordisk shares sink on medicare price negotiation fears
▼ + stars: | 2024-09-17 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovo Nordisk shares sink on medicare price negotiation fearsJared Holz, Mizuho, joins 'Fast Money' to talk how possible Medicare price negotiations are impacting Novo Nordisk shares.

Persons: Jared Holz Organizations: Novo Nordisk Locations: Mizuho

☆ Trade It or Fade It: The week's big biotech moves
▼ + stars: | 2024-09-13 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailTrade It or Fade It: The week's big biotech movesJared Holz, Mizuho, joins 'Fast Money' to talk his playbook on recent biotech movers.

Persons: Jared Holz Locations: Mizuho

☆ Health care bucks sell-off as Eli Lilly soars: Mizuho's Jared Holz on what's next for the group
▼ + stars: | 2024-08-01 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailHealth care bucks sell-off as Eli Lilly soars: Mizuho's Jared Holz on what's next for the groupJared Holz, Mizuho, joins 'Fast Money' to talk resilience in the health care sector as the broader market sees a sell-off.

Persons: Eli Lilly, Jared Holz Organizations: Health Locations: Mizuho

☆ Medicare's drug pricing can give investors certainty on healthcare stocks, says Mizuho's Jared Holz
▼ + stars: | 2024-07-25 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailMedicare's drug pricing can give investors certainty on healthcare stocks, says Mizuho's Jared HolzJared Holz, Mizuho Securities health care equity strategist, joins 'Power Lunch' to discuss healthcare stocks, where he sees the sector heading, and more.

Persons: Jared Holz Jared Holz Organizations: Mizuho Securities Locations: Mizuho

☆ Mizuho's Jared Holz talks Roche shares surging on GLP-1 data
▼ + stars: | 2024-07-17 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailMizuho's Jared Holz talks Roche shares surging on GLP-1 dataJared Holz, Mizuho, joins 'Fast Money' to talk stock movement in the healthcare space on Roche's oral GLP-1 data.

Persons: Jared Holz, Roche Locations: Mizuho

☆ Pfizer is far behind weight loss drug race despite pill trial, says Mizuho's Jared Holz
▼ + stars: | 2024-07-11 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailPfizer is far behind weight loss drug race despite pill trial, says Mizuho's Jared HolzJared Holz, Mizuho, joins 'Fast Money' to talk what impact, if any, the Pfizer weight-loss drug trial will have on the stock.

Persons: Jared Holz Jared Holz Organizations: Pfizer Locations: Mizuho

☆ Eli Lilly's Alzheimer drug is 'a nice additional therapy', says Mizuho's Jared Holz
▼ + stars: | 2024-06-10 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly's Alzheimer drug is 'a nice additional therapy', says Mizuho's Jared HolzJared Holz, Mizuho Securities healthcare equity strategist, joins 'Squawk Box' to discuss the FDA's review of Eli Lilly's experimental Alzheimer drug, whether the drug is a game changer, and more.

Persons: Eli, Jared Holz Jared Holz, Eli Lilly's Organizations: Mizuho Securities Locations: Mizuho

☆ Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared Holz
▼ + stars: | 2024-06-03 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailStructure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared HolzJared Holz, Mizuho, joins 'Fast Money' to talk Structure Therapeutics soaring on its GLP-1 data and M&A targets in the obesity drug space.

Persons: Jared Holz Jared Holz Organizations: Therapeutics Locations: Mizuho

☆ Mizuho’s Jared Holz breaks down UnitedHealth's Q1 earnings
▼ + stars: | 2024-04-16 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailMizuho’s Jared Holz breaks down UnitedHealth's Q1 earningsJared Holz, Mizuho Securities America healthcare equity strategist, joins 'Squawk Box' to break down UnitedHealth's Q1 earnings. The health insurance giant posted first-quarter revenue that beat expectations.

Persons: Jared Holz Organizations: Mizuho Securities

☆ Mizuho's health care earnings playbook ahead of UnitedHealth, J&J results
▼ + stars: | 2024-04-15 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailMizuho's health care earnings playbook ahead of UnitedHealth, J&J resultsJared Holz, Mizuho, joins 'Fast Money' to talk what to expect from the upcoming slate of health care earnings.

Persons: Jared Holz Locations: UnitedHealth, Mizuho

☆ Top AI photo generators produce misleading election-related images, study finds
▼ + stars: | 2024-03-06 | by ( Clare Duffy | ) edition.cnn.com time to read: +7 min

CCDH researchers tested AI image generators Midjourney, Stability AI’s DreamStudio, OpenAI’s ChatGPT Plus and Microsoft Image Creator. They found that each tool could be prompted to create misleading images related to either US presidential candidates or voting security. The researchers also used common “jailbreaking” techniques to try to get around any potential restrictions on creating misleading images. Overall, researchers say they found that the AI image generators created election disinformation in 41% of their test runs. Overall, the platforms were more likely to produce misleading images related to voting and ballots than of candidates.

Persons: David Holz, Donald Trump, CCDH, Trump, Joe Biden, Midjourney, Biden, ” DreamStudio, ”, ’ Organizations: New, New York CNN, CNN, Microsoft, BBC, Trump, ” Locations: New York, United States, American

☆ Mizuho's Jared Holz on finding opportunities in the biotech space
▼ + stars: | 2024-03-06 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailMizuho's Jared Holz on finding opportunities in the biotech spaceJared Holz, Mizuho Securities America healthcare equity strategist, joins 'The Exchange' to discuss why he believes we are in the midst of the most pronounced biotech rally in over five years, whether it’s too late to get in on the trade, and more.

Persons: Jared Holz, it’s Organizations: Mizuho Securities

☆ Eli Lilly and Novo Nordisk will remain leaders in the weight-loss drug market: Mizuho's Jared Holz
▼ + stars: | 2024-02-29 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly and Novo Nordisk will remain leaders in the weight-loss drug market: Mizuho's Jared HolzCNBC’s Melissa Lee and Jared Holz, Mizuho Securities America healthcare sector strategist, join 'Squawk on Street' to discuss the weight-loss drug market, why he believes Eli Lilly and Novo Nordisk will remain the frontrunners for the next 2-3 years, and more.

Persons: Eli Lilly, Jared Holz, Melissa Lee Organizations: Novo Nordisk, Mizuho Securities Locations: Mizuho Securities America

☆ Zealand's obesity drug shouldn't disrupt Novo Nordisk-Eli Lilly leadership: Mizuho's Jared Holz
▼ + stars: | 2024-02-26 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailZealand's obesity drug shouldn't disrupt Novo Nordisk-Eli Lilly leadership: Mizuho's Jared HolzJared Holz, Mizuho, joins 'Fast Money' to talk obesity drugmakers after a new study out of Zealand Pharma analyzed the impact of GLP-1s on liver disease.

Persons: Eli Lilly, Mizuho's Jared Holz Jared Holz Organizations: Novo Nordisk, Zealand Pharma Locations: Mizuho

☆ Eli Lilly hits record high: Here's what investors need to know
▼ + stars: | 2024-02-06 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly hits record high: Here's what investors need to knowJared Holz, Mizuho Securities healthcare strategist, joins 'Squawk on the Street' to discuss why supply imbalances could boost Eli Lilly's future earnings reports, if clients are asking about the company's valuation, and if there will be capacity constraints coming for healthcare companies.

Persons: Eli Lilly, Jared Holz, Eli Lilly's Organizations: Mizuho Securities Locations: Mizuho

☆ Obesity drug supply-demand imbalance is working in Novo Nordisk's favor: Mizuho's Jared Holz
▼ + stars: | 2024-01-31 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailObesity drug supply-demand imbalance is working in Novo Nordisk's favor: Mizuho's Jared HolzJared Holz, Mizuho Securities, joins 'Fast Money' to talk demand in the obesity drug space and who is benefiting from the supply-demand imbalance.

Persons: Jared Holz Jared Holz Organizations: Obesity, Novo Nordisk's, Mizuho Securities Locations: Novo, Mizuho

☆ 'A trove of rebound opportunities': Strategists turn bullish on biotech and more, picking top stocks
▼ + stars: | 2024-01-17 | by ( Weizhen Tan | ) www.cnbc.com time to read: +4 min

2023 wasn't a good year for the health-care sector, but some investors expect it to make a comeback this year — highlighting biotech and medical tech as areas to watch. But now, Citi believes that "astute investors may find themselves with a trove of rebound opportunities." Citi's top picks in biotech include Biomea Fusion , Alnylam Pharmaceuticals , and Immunovant . Jared Holz, health-care sector strategist at Mizuho Securities Americas, named biotech firm Biogen as one of his top trading ideas for 2024. "Biotech has commanded everyone's attention, but the recovery of many best-in-class medical device companies post the GLP-1 selloff has been remarkable," Orton said.

Persons: There's, Jared Holz, Biogen, Trent, medtech, Matt Orton, Orton Organizations: Citi Global Wealth Investments, U.S . Healthcare, Citi, Biomea, Alnylam Pharmaceuticals, Mizuho Securities Americas, Biogen, medtech, Raymond James Investment Management, Medical, Biotech, Abbott Laboratories Locations: U.S, Alphinity, medtech

☆ NASA's James Webb Space Telescope broke its own record to discover the oldest black hole yet, but it has astronomers even more confused about the beginning of the universe
▼ + stars: | 2024-01-17 | by ( Morgan Mcfall-Johnsen | ) www.businessinsider.com time to read: +4 min

Read previewThe James Webb Space Telescope has discovered the oldest black hole ever detected, breaking its own record. It's about 40 million years older than the record-breaking black hole Webb also discovered and announced in November. AdvertisementA cosmic clue in this black hole's outsized appetiteA disk of hot gas swirls around a feeding black hole in this illustration. AdvertisementPeering at the early universe with Webb "is like upgrading from Galileo's telescope to a modern telescope overnight," Maiolino said. He added that his team hopes to search for smaller "seeds" of black holes with future Webb observing time.

Persons: —, James Webb, Webb, Nick Risinger, JWST, Chandra, Daniel Holz, Roberto Maiolino, Maiolino Organizations: Service, Business, ESA, Hubble, Sky Survey, NASA, CSA, University of Chicago, New York Times, University of Cambridge, JPL, Caltech

☆ How Novo Nordisk's ‘select’ study results could shake up the obesity drug space
▼ + stars: | 2023-11-13 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailHow Novo Nordisk's ‘select’ study results could shake up the obesity drug spaceJared Holz, Mizuho, joins 'Fast Money' to talk Novo Nordisk's ‘select’ study and what it means for the obesity drug space.

Persons: Jared Holz Organizations: Nordisk's, Novo Nordisk's Locations: Mizuho

☆ Novo and Eli Lilly stocks could go higher if they show even better data than we think: Mizuho's Holz
▼ + stars: | 2023-11-10 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovo and Eli Lilly stocks could go higher if they show even better data than we think: Mizuho's HolzJared Holz, Mizuho healthcare specialist, joins 'Squawk on the Street' to discuss what to expect from Novo Nordisk's quarterly earnings results, if weight-loss drugs will get covered by insurance, and what's moved Eli Lilly and Novo Nordisk's stocks to this point and future growth prospects.

Persons: Eli Lilly, Jared Holz, what's, Novo Organizations: Email Novo, Novo Locations: Mizuho

☆ Mounjaro remains the single largest driver for Eli Lilly stock in the near term: Mizuho's Jared Holz
▼ + stars: | 2023-11-02 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailMounjaro remains the single largest driver for Eli Lilly stock in the near term: Mizuho's Jared HolzJared Holz, Mizuho healthcare sector specialist, joins 'Squawk on the Street' to discuss what's driving Novo Nordisk and Eli Lilly stocks right now, Holz thoughts on Wegovy, and more.

Persons: Eli Lilly, Jared Holz Jared Holz Organizations: Novo Nordisk Locations: Mizuho

☆ It doesn't seem like there's too much momentum for healthcare stocks, says Mizuho's Jared Holz
▼ + stars: | 2023-10-23 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailIt doesn't seem like there's too much momentum for healthcare stocks, says Mizuho's Jared HolzJared Holz, Mizuho healthcare sector specialist, joins 'Squawk on the Street' to discuss how Holz broadly sees the biotechnology sector, what distills the winners from losers in the healthcare space, and the innovation taking place in healthcare.

Persons: Jared Holz Jared Holz Locations: Mizuho

☆ What other industries could weight loss drugs disrupt?
▼ + stars: | 2023-10-11 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWhat other industries could weight loss drugs disrupt? Jared Holz, Mizuho health care sector strategist, joins the ‘Fast Money’ traders to discuss Novo Nordisj's kidney trial outcomes and the impact of weight loss drugs on the health care sector.

Persons: Jared Holz

Search resuls for: "Holz"

25 mentions found